Targeting A20 enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells

Biochemical and Biophysical Research Communications

Volumn 418, Issue 2, 2012, Pages 433-438

  Dong, Bingfei ^a   Lv, Guoyue ^a   Wang, Quan ^a   Wang, Guangyi ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

A20; Hepatocellular carcinoma; RIP1; TRAIL

Indexed keywords

CASPASE 3; CASPASE 8; CYTOKINE; PROTEIN P18; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DEATH; CELL LYSATE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; UBIQUITINATION; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 8; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; GENE TARGETING; HEP G2 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; NUCLEAR PORE COMPLEX PROTEINS; NUCLEAR PROTEINS; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UBIQUITINATION;

EID: 84862819723     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.01.056     Document Type: Article

References (24)

1. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-2576.
2. Ashkenazi A., Holland P., Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 2008, 26(21):3621-3630.
3. Yamanaka T., Shiraki K., Sugimoto K., Ito T., Fujikawa K., Ito M., Takase K., Moriyama M., Nakano T., Suzuki A. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 2000, 32(3):482-490.
4. Dixit V.M., Green S., Sarma V., Holzman L.B., Wolf F.W., O'Rourke K., Ward P.A., Prochownik E.V., Marks R.M. Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J. Biol. Chem. 1990, 265(5):2973-2978.
5. Hymowitz S.G., Wertz I.E. A20: from ubiquitin editing to tumour suppression. Nat. Rev. Cancer 2010, 10(5):332-341.
6. Vereecke L., Beyaert R., van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009, 30(8):383-391.
7. Heyninck K., Denecker G., De Valck D., Fiers W., Beyaert R. Inhibition of tumor necrosis factor-induced necrotic cell death by the zinc finger protein A20. Anticancer Res. 1999, 19(4B):2863-2868.
8. Daigeler A., Brenzel C., Bulut D., Geisler A., Hilgert C., Lehnhardt M., Steinau H.U., Flier A., Steinstraesser L., Klein-Hitpass L., Mittelkötter U., Uhl W., Chromik A.M. TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J. Exp. Clin. Cancer Res. 2008, 27:82.
9. Hjelmeland A.B., Wu Q., Wickman S., Eyler C., Heddleston J., Shi Q., Lathia J.D., Macswords J., Lee J., McLendon R.E., Rich J.N. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol. 2010, 8(2):e1000319.
10. Lu G., Liu Y., Ji B., Wei F., Hao C., Wang G. Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells. Cancer Invest. 2010, 28(6):629-634.
11. Lerebours F., Vacher S., Andrieu C., Espie M., Marty M., Lidereau R., Bieche I. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 2008, 8:41.
12. Codd J.D., Salisbury J.R., Packham G., Nicholson L.J. A20 RNA expression is associated with undifferentiated nasopharyngeal carcinoma and poorly differentiated head and neck squamous cell carcinoma. J. Pathol. 1999, 187(5):549-555.
13. Guo Q., Dong H., Liu X., Wang C., Liu N., Zhang J., Li B., Cao W., Ding T., Yang Z., Zhang X. A20 is overexpressed in glioma cells and may serve as a potential therapeutic target. Expert Opin. Ther. Targets 2009, 13(7):733-741.
14. Ganten T.M., Haas T.L., Sykora J., Stahl H., Sprick M.R., Fas S.C., Krueger A., Weigand M.A., Grosse-Wilde A., Stremmel W., Krammer P.H., Walczak H. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ. 2004, 11(Suppl 1):S86-S96.
15. Van Geelen C.M., de Vries E.G., de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist. Updat. 2004, 7(6):345-358.
16. Jin Z., Li Y., Pitti R., Lawrence D., Pham V.C., Lill J.R., Ashkenazi A. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009, 137(4):721-735.
17. Kato M., Sanada M., Kato I., Sato Y., Takita J., Takeuchi K., Niwa A., Chen Y., Nakazaki K., Nomoto J., Asakura Y., Muto S., Tamura A., Iio M., Akatsuka Y., Hayashi Y., Mori H., Igarashi T., Kurokawa M., Chiba S., Mori S., Ishikawa Y., Okamoto K., Tobinai K., Nakagama H., Nakahata T., Yoshino T., Kobayashi Y., Ogawa S. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009, 459(7247):712-716.
18. Novak U., Rinaldi A., Kwee I., Nandula S.V., Rancoita P.M., Compagno M., Cerri M., Rossi D., Murty V.V., Zucca E., Gaidano G., Dalla-Favera R., Pasqualucci L., Bhagat G., Bertoni F. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009, 113(20):4918-4921.
19. Compagno M., Lim W.K., Grunn A., Nandula S.V., Brahmachary M., Shen Q., Bertoni F., Ponzoni M., Scandurra M., Califano A., Bhagat G., Chadburn A., Dalla-Favera R., Pasqualucci L. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459(7247):717-721.
20. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441(7092):431-436.
21. Heyninck K., Beyaert R. A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions. Trends Biochem. Sci. 2005, 30(1):1-4.
22. Skaug B., Chen J., Du F., He J., Ma A., Chen Z.J. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol. Cell 2011, 44(4):559-571.
23. Ea C.K., Deng L., Xia Z.P., Pineda G., Chen Z.J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 2006, 22(2):245-257.
24. Wang L., Du F., Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008, 133(4):693-703.